Dr. Liu Huang 黄柳
Chief Physician, Associate Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive diagnosis and treatment of lung, esophageal, breast, gastrointestinal, melanoma, and kidney cancers. Provides screening guidance for malignant tumors and genetic risk counseling for familial cancer clusters.
Dr. Liu Huang holds a PhD in Oncology and was a visiting scholar at Hannover Medical School, Germany. With 11 years of clinical experience, Dr. Huang focuses on lung, esophageal, gastric, melanoma, and kidney cancers. The team translated 80 NCCN oncology guidelines. Dr. Huang holds one National Natural Science Foundation youth grant, participates in multiple national projects, and has published over 20 SCI papers.
Professional roles
- Recipient, CSCO 35 Under 35 Most Promising Young Oncologist (2017)
Name order: in Chinese the family name comes first (Huang Liu). Papers usually list the name as Liu Huang or Huang L.
Selected publications
45 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncogene, 2026 (first author): Oncogenic LPP facilitates focal adhesion maturation in response to mechanical tension and regulates the Hippo signaling. PubMed 41912774
- ACS Nano, 2026 (first author): Noninvasive, Rapid, and Precise Identification of Esophageal Cancer via Salivary Extracellular Vesicle-Based Diagnosis. PubMed 41910207
- Curr Med Sci, 2025 (senior author): Effects of Thymidine Phosphorylase and Sine Oculis Homeobox Homologue 1 on the Prognosis and Immune Microenvironment of Gastric Cancer. PubMed 40522568
- Comput Biol Med, 2025 (senior author): Unraveling the relapse-associated landscape and individualized therapy in stage I lung adenocarcinoma based on immune and mitochondrial metabolism hallmarks via multi-omics analyses. PubMed 39515270
- BMC Cancer, 2024 (senior author): Optimal treatment strategies for hepatoid adenocarcinoma of the lung: insights from a comprehensive analysis. PubMed 39095810
- Front Pharmacol, 2024 (senior author): Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system. PubMed 39045045
- Front Genet, 2022 (senior author): Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma. PubMed 36186480
- Inflammation, 2022 (senior author): Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma. PubMed 35064379
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion